MYT1L and gastric cancer: Consequently, testing for MYT1L rs17039396 SNP, combined with other traditional prognostic factors may significantly help distinguish a subgroup of patients with poor prognosis, thereby helping to refine therapeutic decisions in the treatment of gastric cancer.